Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 248
Appendix H Acronyms AAPAA American Academy of Psychiatrists in Alcoholism and Addiction ABMS American Board of Medical Specialties ABPN American Board of Psychiatry and Neurology ACTH adrenocorticotrophic hormone ADAMHA Alcohol, Drug Abuse, and Mental Health Administration ADD Antiepileptic Drug Development Program ADEPT Alcohol and Drug Education for Physician Training AFDC Aid to Families with Dependent Children AIDS acquired immune deficiency syndrome ALS amyotrophic lateral sclerosis (Lou Gehrig's disease) AMBHA American Managed Behavioral Healthcare Association AMERSA Association for Medical Education and Research in Substance Abuse AMP adenosine 3'5'-monophosphate ASAM American Society of Addiction Medicine ATC addiction training center AZT zidovudine BDC BioDevelopment Corporation BJS Bureau of Justice Statistics BLS Bureau of Labor Statistics BSMD Biobehavioral Sciences and Mental Disorders CALDATA California Drug and Alcohol Treatment Assessment CASA Center on Addiction and Substance Abuse CBO Congressional Budget Office 248
OCR for page 248
APPENDIX H 249 CDC Centers for Disease Control and Prevention CDDA Commission on Medicines for Treatment of Drug Dependence and Abuse CDER Center for Drug Evaluation and Research CDP chemical dependency programs CME continuing medical education CMHS Center for Mental Health Services CNS central nervous system CPDD College on Problems of Drug Dependence CRADAs cooperative research and development agreements CRS Congressional Research Service CSA Controlled Substances Act CSAP Center for Substance Abuse Prevention CSAT Center for Substance Abuse Treatment CTDP Cocaine Treatment Discovery Program DAWN Drug Abuse Warning Network DD drug-discrimination test DEA Drug Enforcement Agency DHHS U.S. Department of Health and Human Services DPC-PTR Drug Price Competition and Patent Term Restoration Act DSRS Drug Services Research Survey DVA Department of Veterans Affairs FDA Food and Drug Administration FDCA Federal Food, Drug, and Cosmetic Act FTEs full-time equivalent personnel FY fiscal year GAO General Accounting Office HIV human immunodeficiency virus HMO health maintenance organization HRSA Health Resources and Services Administration IDU injecting drug-user IND investigational new drug IOM Institute of Medicine IRE institutional review board K20 Scientist Development Award for Clinicians K21 Scientist Development Award LAAM levo-alpha-acetylmethadol (trade name ORLAAM) LMA locomotor-activity test LRP Loan Repayment Program MARC Minority Access to Research Careers MDD Medications Development Division MDMA Methylenedioxymethamphetamine ("ecstacy")
OCR for page 248
250 DEVELOPMENT OF MEDICATIONS MSH melanocyte-stimulating hormone NAS National Academy of Sciences NASADAD National Association of State Alcohol and Drug Abuse Directors, Inc. NATA Narcotic Addict Treatment Act NCDDG-AIDS National Cooperative Drug Discovery Groups on Acquired Immune Deficiency Syndrome NCI National Cancer Institute NCJA National Criminal Justice Association NDA new drug application NDATUS National Drug and Alcoholism Treatment Survey NIAAA National Institute on Alcohol Abuse and Alcoholism Administration NIAID National Institute of Allergy and Infectious Diseases NIDA National Institute on Drug Abuse NIH National Institutes of Health NRC National Research Council NRSA National Research Service Awards ODE out-patient drug-free ONDCP Office of National Drug Control Policy OPRR Office of Protection from Research Risks ORLAAMrM levo-alpha-acetylmethadol (LAAM) OTA Office of Technology Assessment PBMs pharmaceutical benefit managers PCP phencyclidine PhRMA Pharmaceutical Research and Manufacturers of America PHS Public Health Service PMA Pharmaceutical Manufacturers Association POMC pro-opiomelanocortin R&D research and development R01 investigator-initiated grants R18 research-demonstration grants SA self-administration test SADAP State Alcohol and Drug Abuse Profile SAMHSA Substance Abuse and Mental Healtn Services Administration SSI Supplemental Security Income TB tuberculosis Tcs therapeutic communities TOPS Treatment Outcome Prospective Study TRUs treatment research units VA Department of Veterans Affairs WHO World Health Organization